The announced 2nd annual Biosimilars Congress India 2017, by CPhI Conferences, a division of UBM India, which hosts a number of successful pharmaceutical conferences in the country is slated for 8th(today) - 9th August in Hyderabad.

The Indian biosimilar industry is poised for exponential growth owing to the increasing acceptance, entry of new players, and successful launch of biosimilar products. The Indian biosimilar manufacturers are striving to tap this growing opportunity through heavy investments and acquisitions. While biosimilars offer great opportunities to the Indian pharma and biopharma industry, manufacturers also face some unique R&D challenges. With the introduction of a new regulatory policy in India and increased affordability that biosimilars offer, the Indian pharmaceutical companies have started to look at biosimilars as a lucrative sector. The domestic market is expected to grow at an accelerated pace by aiming to reach a target of USD 40 billion by 2030 and commanding around 20 per cent share of the global market.

CPhI's 2nd annual Biosimilars Congress India 2017 will discuss various aspects around regulations of biosimilars, R&D, clinical research, program management and commercialisation for biosimilars. Driven by compelling content and speakers, the congress promises to be a platform for industry experts and decision makers to discuss on pertinent trends in biosimilars, deliberate on key concerns the industry faces today and offer innovative solutions that will continue to place India on the roadmap to success in biosimilars. The congress will also have practical case study insights from Indian and international experts along with panel discussions with a Q&A session.

Speaking on the upcoming 2nd Annual Biosimilars Congress India, Yogesh Mudras, Managing Director, UBM India said, "Biosimilar pathways are still evolving across the world and the major issues pharma companies face are with respect to demonstrating biosimilarity to the reference product. The changing outlook for Biosimilars comes at a time when the global pharmaceutical industry is feeling the combined impact of two key events - a period of patent expirations on many large pharma brands, and an economic situation that has required healthcare systems to make significant and sustained cost reductions. CPhI's 2nd annual Biosimilars Congress thus comes at the right time, and aims to bring forth the challenges and opportunities to industry professionals, so that they can devise smart strategies to augment the growth of biosimilars."

The conference will also see participation from eminent speakers such as Cecil Nick, Vice President (Technical), Integrated Product Development, PAREXEL; Bhaswat S. Chakraborty, Senior Vice President, Research & Development, Cadila Pharmaceuticals Ltd; Akshaya S. Odak, Senior Director - Regulatory, Lupin; Narendra Chirmule, Senior Vice President, Head of Research and Development, Biocon; A. K. S. Bhujanga Rao, President of R&D and Technical, Natco Pharma; Anjan Selz, Vice President - Head of Biosimilars EMEA, Lupin - Atlantis Holdings SA; Sunit Maity, Director Product Development, Zumutor Biologics any more sharing their perspective about the various biosimilar aspects of the pharma industry.